| Ms Thao Le Langnas, | |
|
1900 1st Capitol Dr, Saint Charles, MO 63301-1609 | |
| (636) 946-0738 | |
| (636) 946-0775 |
| Full Name | Ms Thao Le Langnas |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1900 1st Capitol Dr, Saint Charles, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093291122 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 044796 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Thao Le Langnas, 1900 1st Capitol Dr, Saint Charles, MO 63301-1609 Ph: (636) 946-0738 | Ms Thao Le Langnas, 1900 1st Capitol Dr, Saint Charles, MO 63301-1609 Ph: (636) 946-0738 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.
Despite major progress in diagnosis and treatment, diabetic retinopathy remains the major cause of blindness in adults under 60 in the U.S., said Thomas C. Lee, director, Retina Institute in The Vision Center at Childrens Hospital Los Angeles, associate professor of clinical ophthalmology at the Keck School of Medicine of the University of Southern California and attending physician at Doheny Eye Institute.
Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data for its selective HDAC1/2 inhibitors for the treatment of sickle cell disease (SCD) and β-thalassemia (bT) were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.
› Verified 1 days ago
Christina Lynn Crump, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 147 Foxtail Dr, Saint Charles, MO 63303 Phone: 314-623-7611 Fax: 636-949-6945 | |
Megan Mcvicar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3800 Elm St, Saint Charles, MO 63301 Phone: 636-724-6628 | |
Jeffrey Frank Allen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1780 Zumbehl Rd, Saint Charles, MO 63303 Phone: 636-723-1134 | |
Maria Maull, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1039 S Duchesne Dr, Saint Charles, MO 63301 Phone: 636-724-4848 | |
Dr. David N Maywright, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 1st Capitol Dr, Saint Charles, MO 63301 Phone: 314-541-9482 | |
Brent Tackitt, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1768 Winding Glen Dr, Saint Charles, MO 63303 Phone: 618-292-8476 | |
Michael Frederick, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2855 Veterans Memorial Parkway, (pharmacy), Saint Charles, MO 63303 Phone: 636-925-1143 |